Search Result

Results for "

integrins

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Integrin (171) Akt (2) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (18) Autophagy (6) Bcr-Abl (1) Biochemical Assay Reagents (3) Btk (1) c-Kit (1) C-type Lectin-like Receptors (CTLRs) (1) Caspase (2) Complement System (3) DNA Methyltransferase (1) Drug Intermediate (1) DYRK (1) EGFR (1) Elastase (1) Endogenous Metabolite (5) Factor Xa (1) FAK (7) Fluorescent Dye (1) Free Fatty Acid Receptor (1) Glutaminase (1) Glycoprotein VI (1) HSP (1) IKK (1) Isotope-Labeled Compounds (3) MDM-2/p53 (1) MMP (2) Molecular Glues (1) mTOR (1) NF-κB (2) NOD-like Receptor (NLR) (1) p38 MAPK (2) PD-1/PD-L1 (1) PI3K (4) Potassium Channel (1) Radionuclide-Drug Conjugates (RDCs) (1) Ras (1) Reactive Oxygen Species (1) Sialyltransferase (1) Src (7) STAT (1) Syk (1) TGF-beta/Smad (1) VEGFR (1) Wnt (2) β-catenin (1)
By Research Areas:	Cancer (106) Cardiovascular Disease (33) Infection (3) Inflammation/Immunology (70) Metabolic Disease (8) Neurological Disease (4)

By Targets:

Integrin (171)

Akt (2)

Antibody-Drug Conjugates (ADCs) (1)

Apoptosis (18)

Autophagy (6)

Bcr-Abl (1)

Biochemical Assay Reagents (3)

Btk (1)

c-Kit (1)

C-type Lectin-like Receptors (CTLRs) (1)

Caspase (2)

Complement System (3)

DNA Methyltransferase (1)

Drug Intermediate (1)

DYRK (1)

EGFR (1)

Elastase (1)

Endogenous Metabolite (5)

Factor Xa (1)

FAK (7)

Fluorescent Dye (1)

Free Fatty Acid Receptor (1)

Glutaminase (1)

Glycoprotein VI (1)

HSP (1)

IKK (1)

Isotope-Labeled Compounds (3)

MDM-2/p53 (1)

MMP (2)

Molecular Glues (1)

mTOR (1)

NF-κB (2)

NOD-like Receptor (NLR) (1)

p38 MAPK (2)

PD-1/PD-L1 (1)

PI3K (4)

Potassium Channel (1)

Radionuclide-Drug Conjugates (RDCs) (1)

Ras (1)

Reactive Oxygen Species (1)

Sialyltransferase (1)

Src (7)

STAT (1)

Syk (1)

TGF-beta/Smad (1)

VEGFR (1)

Wnt (2)

β-catenin (1)

By Research Areas:

Cancer (106)

Cardiovascular Disease (33)

Infection (3)

Inflammation/Immunology (70)

Metabolic Disease (8)

Neurological Disease (4)

201

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Integrin

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-134130

Integrin modulator 1	Integrin	Inflammation/Immunology
Integrin modulator 1 is a potent and selective α4β1 integrin agonist, with an IC₅₀ of 9.8 nM for RGD-binding α4β1. Integrin modulator 1 increases cell adhesion mediated by α4β1 integrin, with an EC₅₀ of 12.9 nM .

HY-P3523

KGDS	Integrin	Others
KGDS is synthetic peptides, targeting integrin GPIIb-IIIa located on the membrane of human activated platelets. Amino acid sequence: Lys-Gly-Asp-Ser .

HY-P1654

A20FMDV2	Integrin	Cancer
A20FMDV2 is a selective αvβ6 integrin inhibitor (IC₅₀: 3 nM), with an activity 1,000-fold more selective for αvβ6 than for other RGD-directed integrins (αvβ3, αvβ5, and α5β1). A20FMDV2 can be derived from the foot-and-mouth disease virus. A20FMDV2 can be radiolabeled for the PET imaging of αvβ6 integrin-positive tumors .

HY-P0178

LXW7	Integrin	Inflammation/Immunology
LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC₅₀ of 0.68 μM. LXW7 increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect .

HY-P1930A

Risuteganib hydrochloride	Integrin	Inflammation/Immunology
Risuteganib hydrochloride is a synthetic RGD (arginyl-glycyl-aspartic acid)-class peptide. Risuteganib hydrochloride is an anti-integrin that downregulates oxidative stress and restores homeostasis, and targets three integrin receptors that are implicated in dry age-related macular degeneration (AMD) in order to restore homeostasis in the retina .

HY-P10045

Integrin signaling inhibitor, mP13	Integrin	Cardiovascular Disease
Integrin signaling inhibitor, mP13 is an inhibitor of integrin signaling. Integrin signaling inhibitor, mP13 inhibits inside-out and outside-in signaling, including fibrinogen binding, platelet adhesion, and clot retraction .

HY-161730

*αvβ1 integrin-IN-3*	Integrin	Cardiovascular Disease Cancer
αvβ1 integrin-IN-3 is a selective αvβ1 integrin inhibitor. αvβ1 integrin-IN-3 has an antifibrotic effect .

HY-150124

K34c	Integrin	Cancer
K34c is a potent and selective α5β1 integrin antagonist. K34c can be used for glioblastoma research .

HY-P1930

Risuteganib	Integrin	Inflammation/Immunology
Risuteganib is a synthetic RGD (arginyl-glycyl-aspartic acid)-class peptide. Risuteganib is an anti-integrin that downregulates oxidative stress and restores homeostasis, and targets three integrin receptors that are implicated in dry age-related macular degeneration (AMD) in order to restore homeostasis in the retina .

HY-136214

R-BC154 acetate	Integrin	Inflammation/Immunology Cancer
R-BC154 acetate is a selective fluorescent α₉β₁ integrin antagonist. R-BC154 acetate acts as a useful high affinity, activation dependent integrin probe, which can be used to investigate α9β1 and α4β1 integrin binding activity .

HY-P0023

Cyclo(-RGDfK) 15+ Cited Publications	Integrin	Cancer
Cyclo(-RGDfK) is a potent and selective inhibitor of the α_vβ₃ integrin, with an IC₅₀ of 0.94 nM . Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface .

HY-P0178A

LXW7 TFA	Integrin	Inflammation/Immunology
LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC₅₀ of 0.68 μM. LXW7 TFA increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect .

HY-123802

BIO7662	Integrin	Cancer
BIO7662 is a specific α4β1 antagonist. BIO7662 can be used to study α4β1 integrin-ligand interactions .

HY-P0023A

Cyclo(-RGDfK) TFA 15+ Cited Publications	Integrin	Cancer
Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the α_vβ₃ integrin, with an IC₅₀ of 0.94 nM . Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface .

HY-P0322

GRGDSPK EMD 56574	Integrin	Cardiovascular Disease Metabolic Disease
GRGDSPK (EMD 56574) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK (EMD 56574) is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK is used to study the role of integrins in bone formation and resorption .

HY-P0322A

GRGDSPK TFA EMD 56574 TFA	Integrin	Cardiovascular Disease Metabolic Disease
GRGDSPK TFA (EMD 56574 TFA) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK TFA is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK TFA is used to study the role of integrins in bone formation and resorption .

HY-P10417

RTDLDSLRTYTL	Integrin	Others Cancer
RTDLDSLRTYTL is an Alpha (v) beta (6) integrin (avb6) inhibitor with high affinity and specificity. RTDLDSLRTYTL binds to avb6 integrin, a peptide sequence that activates cytotoxicity and cytokine production in T cells, such as interferon-gamma. RTDLDSLRTYTL is designed through a chimeric T cell antigen receptor (CAR) so that T cells can be redirected to specifically recognize and attack tumor cells. RTDLDSLRTYTL can be used in the research of cancer immunotherapy and targeted drug development .

HY-139137

N-Acetyl-S-geranylgeranyl-L-cysteine AGGC	DNA Methyltransferase Integrin	Cancer
N-Acetyl-S-geranylgeranyl-L-cysteine is a Methyltransferase inhibitor. N-Acetyl-S-geranylgeranyl-L-cysteine inhibits beta 2 integrin-induced actin polymerization with an IC₅₀ of 45 nM .

HY-P3732

RGD-4C	Integrin	Cancer
RGD-4C is a arginine-glycine-aspartic acid peptide (ACDCRGDCFC) with integrin binding activity. The Arg-Gly-Asp (RGD) sequence serves as the primary integrin recognition site in extracellular matrix proteins, and peptides containing this sequence can mimic the recognition specificity of the matrix proteins. RGD-4C is a αv-integrin ligand, can conjugate with bioactive molecule to exert antitumor effects in animal models .

HY-145363

*αvβ5 integrin-IN-1*	Integrin	Cancer
Sulodexide (pIC₅₀ = 8.2 nM) selectively binds to the αvβ5 integrin in K562 and A549 cell lines and exhibits a significant inhibitory effect .

HY-129453

BOP sodium	Integrin	Inflammation/Immunology
BOP sodium is a potent and selective dual α9β1/α4β1 integrin inhibitor with K_d values in the picomolar range. BOP sodium shows the rapid and preferential mobilization of hematopoietic stem cell (HSC) and progenitors. BOP sodium has little inhibitory activity on α4β7, α1β1, α2β1, and α5β1, αIIBβ3 integrins .

HY-P4896

FITC-Ahx-Gly-Arg-Gly-Asp-Ser-Pro	Integrin	Cancer
FITC-Ahx Gly Arg Gly Asp Ser Pro is a GRGDSP (HY-P0290) coupled to FITC. GRGDSP is an *integrin* inhibitor that can inhibit the adherence of tumor cells to endothelial cells of blood vessels and limit its metastasis .

HY-115677

ILK-IN-3	Integrin DYRK	Cancer
ILK-IN-3 is an orally active integrin linked kinase (ILK) inhibitor. ILK-IN-3 improves the anticancer efficacy of Docetaxel (HY-B0011) in orthotopic LCC6 model .

HY-P3533

EILEVPST	Integrin	Cardiovascular Disease
EILEVPST is a recombinant human fibronectinderived low-molecular-weight peptide fragment. EILEVPST can promote cell type-specific α4 integrin-mediated adhesion. EILEVPST can be used for the research of thrombogenesis .

HY-16141

Cilengitide Maximum Cited Publications 46 Publications Verification EMD 121974	Integrin Autophagy Apoptosis STAT PD-1/PD-L1	Cancer
Cilengitide (EMD 121974) is a potent *integrins* antagonist with IC₅₀s of 0.61 nM (α_νβ₃), 8.4 nM (α_νβ₅) and 14.9 nM (α₅β₁), respectively. Cilengitide inhibits the binding of α_νβ₃ and α_νβ₅ to Vitronectin with IC₅₀s of 4 nM and 79 nM, respectively. Cilengitide inhibits TGF-β/Smad signaling, mediates PD-L1 expression. Cilengitide also induces apoptosis, shows antiangiogenic effect in the research against glioblastoma and other cancers .

HY-P1613

Cyclo(Arg-Gly-Asp-D-Phe-Val) Cyclo(RGDfV); C(RGDfV)	Integrin Apoptosis	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Val) (Cyclo(RGDfV)) is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) can be used for the research of acute myeloid leukemia .

HY-P9984

Etrolizumab 2 Publications Verification rhuMAb Beta7; RG7413; PRO145223	Integrin	Cancer
Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with K_i values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD) .

HY-P990643

OS-2966	Integrin	Inflammation/Immunology
OS-2966 is a humanized antibody expressed in CHO cells, targeting Integrin b1/ITGB1/CD29. OS-2966 carries a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.5 kDa. The isotype control for OS-2966 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-W008859

Tetrac 1 Publications Verification Tetraiodothyroacetic acid; 3,3',5,5'-Tetraiodothyroacetic acid	Integrin Endogenous Metabolite	Cancer
Tetrac (Tetraiodothyroacetic acid), a derivative of L-thyroxine (T4), is a thyrointegrin receptor antagonist. Tetrac blocks the actions of T4 and 3,5,3'-triiodo-L-thyronine (T3) at the cell surface receptor for thyroid hormone on integrin αvβ3. Tetra has anti-angiogenic and anti-tumor activities .

HY-P1613A

Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA Cyclo(RGDfV) TFA; C(RGDfV) TFA	Integrin Apoptosis	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) (Cyclo(RGDfV) (TFA))is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) can be used for the research of acute myeloid leukemia .

HY-P99560

Tadocizumab C4G1; YM-337	Integrin	Cardiovascular Disease
Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody tageting integrin αIIbβ3. Tadocizumab has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research .

HY-108831A

Natalizumab (Solution) 2 Publications Verification	Integrin	Inflammation/Immunology Cancer
Natalizumab (Solution) is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses .

HY-P3448

Certepetide CEND-1; iRGD; LSTA1	Integrin Complement System	Cancer
Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with *alphav-integrins* and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors .

HY-137561A

Bexotegrast hydrochloride PLN-74809 hydrochloride	Integrin	Inflammation/Immunology
Bexotegrast hydrochloride (PLN-74809 hydrochloride) is a small molecule dual selective inhibitor with activity targeting αVβ1 and αVβ6. Bexotegrast hydrochloride is used for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). Bexotegrast hydrochloride inhibits the activation of TGF-β1 by blocking the function of these integrins, thereby preventing the growth of fibrous tissue in the lungs and bile ducts .

HY-15770

TR-14035 5 Publications Verification	Integrin	Inflammation/Immunology
TR-14035 is a orally active dual α₄β₇/α₄β₁ integrin antagonist, with IC₅₀ s of 7 nM and 87 nM for α₄β₇ and α₄β₁, respectively. TR-14035 can be used for the research of inflammation and autoimmune diseases .

HY-P99184

Abrilumab	Integrin	Infection Inflammation/Immunology Cancer
Abrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD) .

HY-E70297

N-Acetylglucosaminyltransferase IVa MGAT4A	Endogenous Metabolite	Cancer
N-Acetylglucosaminyltransferase IVa (MGAT4A) is a glycosyltransferase that can enhance the migration, invasion, and adhesion abilities of cancer cells, and increase β1,4GlcNAc branched glycans on integrin β1 (ITGB1), a tumor-associated glycoprotein closely related to cell motility .

HY-P990667

STX-100	Integrin	Inflammation/Immunology
STX-100 is a humanized antibody expressed in CHO cells, targeting Integrin aVb6 (ITGAV & ITGB6). STX-100 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.12 kDa. The isotype control for STX-100 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-137561

Bexotegrast PLN-74809	Integrin	Inflammation/Immunology
Bexotegrast (PLN-74809) is an orally active, potent dual αvβ6/αvβ1 integrin inhibitor with K_d of 5.7 nM and 3.4 nM, respectively. Bexotegrast inhibits αvβ6- and αvβ1-induced TGF-β activation with IC₅₀ values of 29.8 nM and 19.2 nM, respectively. Bexotegrast has antifibrogenic effects and block multiple avenues of TGF-β activation in the fibrotic lung .

HY-P6022

*G4RGDSP, integrin-binding peptide*	Integrin	Others
G4RGDSP, Integrin-binding peptide is a cell integrin-binding peptide that targets integrin receptors. G4RGDSP, integrin-binding peptide is coupled to alginate to increase the viability of cells in the scaffold. G4RGDSP, integrin-binding peptide can be used as an extrudable carrier for chondrocyte delivery for the study of 3D printing technology

HY-70073

Zaurategrast 2 Publications Verification CT7758	Integrin	Inflammation/Immunology
Zaurategrast (CT7758) is a potent and oral-effective *α₄-integrin* inhibitor .

HY-P2532

Integrin Binding Peptide	Integrin	Others
Integrin Binding Peptide is derived by fibronectin. Integrin Binding Peptide can be used for PEG hydrogel preparation .

HY-100506

GLPG0187 10+ Cited Publications	Integrin	Cancer
GLPG0187 is a broad spectrum *integrin* receptor antagonist with antitumor activity; inhibits α_vβ₁-integrin with an IC₅₀ of 1.3 nM . GLPG0187 inhibits migrasome biogenesis without cytotoxicity .

HY-P9911A

*Vedolizumab (anti-α4β7-integrin)*	Integrin	Inflammation/Immunology
Vedolizumab (anti-α4β7-integrin) is a humanized IgG1 monoclonal antibody that targets the α4β7 *integrin* for the treatment of ulcerative colitis and Crohn's disease .

HY-48959

*α7β1 integrin* modulator-1**	Integrin	Metabolic Disease
α7β1 integrin modulator-1 is a potent α7β1 integrin modulator. α7β1 integrin modulator-1 has the potential for the research of muscular dystrophy .

HY-18668

Integrin antagonist 27	Integrin	Cancer
Integrin antagonist 27 is a small molecule integrin αvβ3 antagonist with binding affinity of 18 nM, as s novel anticancer agent.

HY-107588

TC-I 15 1 Publications Verification	Integrin	Cardiovascular Disease
TC-I 15 (TC-I-15) is a type of allosteric collagen-binding integrin α2β1 inhibitor, and it also inhibits α1β1 and α11β1. TC-I 15 inhibits platelet adhesion to collagen and thrombus deposition. TC-I 15 prevents the formation of a pre-metastatic microenvironment by inhibiting the uptake of cancer-associated fibroblast (CAF) extracellular vesicles (EVs) by lung fibroblasts, which reduces the metastasis of salivary gland adenocystic carcinoma (SACC) to the lungs in mouse models, .

HY-139702

*α5β1 integrin* agonist-1**	Integrin	Cancer
α5β1 integrin agonist-1, acting as α5β1 integrin agonist, is able to selectively deliver 5-FU into tumor cells, successfully leading to cancer cell death.

HY-153807

*αvβ6 integrin* inhibitor 2**	Integrin	Inflammation/Immunology
αvβ6 integrin inhibitor 2 is a potent ανβ6 integrin inhibitor with an IC₅₀ of 96.5 nM (WO2020081154A1, example 19) .

HY-P0290A

GRGDSP TFA 5 Publications Verification	Integrin	Cancer
GRGDSP (TFA) is an *integrin* inhibitor.

Cat. No.	Product Name	Type

HY-D2439

RGD-PEG-Cy3

Fluorescent Dyes/Probes

RGD-PEG-Cy3 is a fluorescent labeling reagent that combines Cy3 fluorescent dye, peptide (RGD) and polyethylene glycol (PEG). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Cy3 has an emission maximum around 562-570 nm. RGD is a peptide sequence (CRGDKGPDCiRGD) that binds to αvβ3 and αvβ5 integrin receptors on tumor neovasculogenesis to achieve specific tumor tissue targeting .

Cat. No.	Product Name	Type

HY-111413A

c(phg-isoDGR-(NMe)k) TFA	Chelators
c(phg-isoDGR-(NMe)k) TFA is a selective and potent *α5β1-integrin* ligand with an IC₅₀ of 2.9 nM .

HY-P3160

Fibronectin 3 Publications Verification	Native Proteins
Fibronectin, a glycoprotein present in blood as well as in cells, is a biomarker of tissue injury. Fibronectin binds to membrane-spanning receptor proteins called integrins. Fibronectin also binds to other extracellular matrix proteins such as collagen, fibrin, and heparan sulfate proteoglycans .

HY-100133A

DOTA-ADIBO TFA	Chelators
DOTA-ADIBO TFA is a DOTA-derived bifunctional chelator (BFC) that allows drug conjugation via an uncatalyzed, copper-free cycloaddition reaction. DOTA-ADIBO TFA enables the construction of fusion chelator systems that can be further used to synthesize radiotracers after Cu[64] modification. Positron emission tomography imaging of tumors expressing integrin αvβ6 .

HY-P2975

Laminin β2 (Engelbreth-Holm-Swarm murine sarcoma basement membrane)

Mouse laminin (Engelbreth-Holm-Swarm murine sarcoma basement membrane)

Native Proteins

Laminin β2 (Engelbreth-Holm-Swarm murine sarcoma basement membrane) is a crucial structural element in animal tissues, forming part of the scaffolding that supports tissue architecture. It interacts with type IV collagen through entactin and perlecan, connects to cell membranes via integrin receptors, dystroglycan complexes, and Lutheran blood group glycoproteins, and contains functional domains that facilitate collagen binding, cell adhesion, heparin interaction, and promote neurite outgrowth.

HY-NP132

Recombinant Humanized Type III Collagen 28.6kDa

Native Proteins

Recombinant Humanized Type III Collagen 28.6kDa is a type III collagen 28.6kDa. Recombinant humanized type III collagen (rhCOLIII) has various biological functions, such as promoting skin extracellular matrix regeneration and improving the cell microenvironment. rhCOLIII inhibits the proliferation, migration, and invasion of breast cancer cells. Type III collagen functions in cell adhesion, migration, proliferation and differentiation through its interaction with integrins .

HY-111413

c(phg-isoDGR-(NMe)k)	Chelators
c(phg-isoDGR-(NMe)k) is a selective and potent *α5β1-integrin* ligand with an IC₅₀ of 2.9 nM .

HY-NP132A

Recombinant humanized type III collagen (MW 55900)

Native Proteins

Recombinant humanized type III collagen (MW 55900) is a type III collagen with a molecular weight of 55900 Da. Recombinant humanized type III collagen has various biological functions, such as promoting skin extracellular matrix regeneration and improving the cell microenvironment. Recombinant humanized type III collagen inhibits the proliferation, migration, and invasion of breast cancer cells. Type III collagen functions in cell adhesion, migration, proliferation and differentiation through its interaction with integrins .

Cat. No.	Product Name	Target	Research Area

HY-P3523

KGDS	Integrin	Others
KGDS is synthetic peptides, targeting integrin GPIIb-IIIa located on the membrane of human activated platelets. Amino acid sequence: Lys-Gly-Asp-Ser .

HY-P1654

A20FMDV2	Integrin	Cancer
A20FMDV2 is a selective αvβ6 integrin inhibitor (IC₅₀: 3 nM), with an activity 1,000-fold more selective for αvβ6 than for other RGD-directed integrins (αvβ3, αvβ5, and α5β1). A20FMDV2 can be derived from the foot-and-mouth disease virus. A20FMDV2 can be radiolabeled for the PET imaging of αvβ6 integrin-positive tumors .

HY-P0178

LXW7	Integrin	Inflammation/Immunology
LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC₅₀ of 0.68 μM. LXW7 increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect .

HY-P1930A

Risuteganib hydrochloride	Integrin	Inflammation/Immunology
Risuteganib hydrochloride is a synthetic RGD (arginyl-glycyl-aspartic acid)-class peptide. Risuteganib hydrochloride is an anti-integrin that downregulates oxidative stress and restores homeostasis, and targets three integrin receptors that are implicated in dry age-related macular degeneration (AMD) in order to restore homeostasis in the retina .

HY-P0023

Cyclo(-RGDfK) Maximum Cited Publications 18 Publications Verification	Integrin	Cancer
Cyclo(-RGDfK) is a potent and selective inhibitor of the α_vβ₃ integrin, with an IC₅₀ of 0.94 nM . Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface .

HY-P0178A

LXW7 TFA	Integrin	Inflammation/Immunology
LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC₅₀ of 0.68 μM. LXW7 TFA increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect .

HY-P0023A

Cyclo(-RGDfK) TFA Maximum Cited Publications 18 Publications Verification	Integrin	Cancer
Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the α_vβ₃ integrin, with an IC₅₀ of 0.94 nM . Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface .

HY-P0322

GRGDSPK EMD 56574	Integrin	Cardiovascular Disease Metabolic Disease
GRGDSPK (EMD 56574) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK (EMD 56574) is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK is used to study the role of integrins in bone formation and resorption .

HY-P10045

Integrin signaling inhibitor, mP13	Integrin	Cardiovascular Disease
Integrin signaling inhibitor, mP13 is an inhibitor of integrin signaling. Integrin signaling inhibitor, mP13 inhibits inside-out and outside-in signaling, including fibrinogen binding, platelet adhesion, and clot retraction .

HY-P1930

Risuteganib	Integrin	Inflammation/Immunology
Risuteganib is a synthetic RGD (arginyl-glycyl-aspartic acid)-class peptide. Risuteganib is an anti-integrin that downregulates oxidative stress and restores homeostasis, and targets three integrin receptors that are implicated in dry age-related macular degeneration (AMD) in order to restore homeostasis in the retina .

HY-P0322A

GRGDSPK TFA EMD 56574 TFA	Integrin	Cardiovascular Disease Metabolic Disease
GRGDSPK TFA (EMD 56574 TFA) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK TFA is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK TFA is used to study the role of integrins in bone formation and resorption .

HY-P10417

RTDLDSLRTYTL	Integrin	Others Cancer
RTDLDSLRTYTL is an Alpha (v) beta (6) integrin (avb6) inhibitor with high affinity and specificity. RTDLDSLRTYTL binds to avb6 integrin, a peptide sequence that activates cytotoxicity and cytokine production in T cells, such as interferon-gamma. RTDLDSLRTYTL is designed through a chimeric T cell antigen receptor (CAR) so that T cells can be redirected to specifically recognize and attack tumor cells. RTDLDSLRTYTL can be used in the research of cancer immunotherapy and targeted drug development .

HY-P3732

RGD-4C	Integrin	Cancer
RGD-4C is a arginine-glycine-aspartic acid peptide (ACDCRGDCFC) with integrin binding activity. The Arg-Gly-Asp (RGD) sequence serves as the primary integrin recognition site in extracellular matrix proteins, and peptides containing this sequence can mimic the recognition specificity of the matrix proteins. RGD-4C is a αv-integrin ligand, can conjugate with bioactive molecule to exert antitumor effects in animal models .

HY-P4896

FITC-Ahx-Gly-Arg-Gly-Asp-Ser-Pro	Integrin	Cancer
FITC-Ahx Gly Arg Gly Asp Ser Pro is a GRGDSP (HY-P0290) coupled to FITC. GRGDSP is an *integrin* inhibitor that can inhibit the adherence of tumor cells to endothelial cells of blood vessels and limit its metastasis .

HY-P3533

EILEVPST	Integrin	Cardiovascular Disease
EILEVPST is a recombinant human fibronectinderived low-molecular-weight peptide fragment. EILEVPST can promote cell type-specific α4 integrin-mediated adhesion. EILEVPST can be used for the research of thrombogenesis .

HY-P1613

Cyclo(Arg-Gly-Asp-D-Phe-Val) Cyclo(RGDfV); C(RGDfV)	Integrin Apoptosis	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Val) (Cyclo(RGDfV)) is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) can be used for the research of acute myeloid leukemia .

HY-P1613A

Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA Cyclo(RGDfV) TFA; C(RGDfV) TFA	Integrin Apoptosis	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) (Cyclo(RGDfV) (TFA))is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) can be used for the research of acute myeloid leukemia .

HY-P3448

Certepetide CEND-1; iRGD; LSTA1	Integrin Complement System	Cancer
Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with *alphav-integrins* and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors .

HY-P6022

*G4RGDSP, integrin-binding peptide*	Integrin	Others
G4RGDSP, Integrin-binding peptide is a cell integrin-binding peptide that targets integrin receptors. G4RGDSP, integrin-binding peptide is coupled to alginate to increase the viability of cells in the scaffold. G4RGDSP, integrin-binding peptide can be used as an extrudable carrier for chondrocyte delivery for the study of 3D printing technology

HY-P2532

Integrin Binding Peptide	Integrin	Others
Integrin Binding Peptide is derived by fibronectin. Integrin Binding Peptide can be used for PEG hydrogel preparation .

HY-P0290A

GRGDSP TFA 5 Publications Verification	Integrin	Cancer
GRGDSP (TFA) is an *integrin* inhibitor.

HY-P3522

REDV	Integrin	Cancer
REDV is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV can mediate adhesion to the IIICS region of plasma fibronectin by binding the integrin alpha 4 beta 1(α4β1). REDV can be used for the research of cell adhesion .

HY-P1868

*α2β1 Integrin* Ligand Peptide** 2 Publications Verification DGEA peptide	Integrin	Infection
α2β1 Integrin Ligand Peptide interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors .

HY-P0290

GRGDSP 5 Publications Verification	Integrin	Cancer
GRGDSP, a synthetic linear RGD peptide, is an *integrin* inhibitor.

HY-P1868A

*α2β1 Integrin* Ligand Peptide TFA** 2 Publications Verification DGEA peptide TFA	Integrin	Others
α2β1 Integrin Ligand Peptide TFA interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors .

HY-P2267

LDV 1 Publications Verification	Integrin	Others
LDV is a non-fluorescent analog of LDV-FITC. LDV is a α4β1 integrin (VLA-4) ligand, and binds α4β1 integrin in leukemia cells .

HY-P3522A

REDV TFA	Integrin	Cancer
REDV TFA is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV TFA can mediate adhesion to the IIICS region of plasma fibronectin by binding the integrin alpha 4 beta 1(α4β1). REDV TFA can be used for the research of cell adhesion .

HY-P5812

IDR 1002	Integrin	Inflammation/Immunology
IDR-1002 is an anti-infective peptide that enhances the ability of human monocytes to migrate toward chemokines on fibronectin. IDR-1002 also induces adhesion and activation of β1-integrin, a mechanism that promotes monocyte recruitment .

HY-12290

Arg-Gly-Asp-Ser 5 Publications Verification RGDS peptide; Fibronectin tetrapeptide	Integrin	Inflammation/Immunology
Arg-Gly-Asp-Ser is an integrin binding sequence that inhibits integrin receptor function. Arg-Gly-Asp-Ser directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1.

HY-100563

Cyclo(RGDyK) trifluoroacetate 3 Publications Verification	Integrin	Cancer
Cyclo(RGDyK) trifluoroacetate is a potent and selective α_Vβ₃ integrin inhibitor with an IC₅₀ of 20 nM.

HY-100563A

Cyclo(RGDyK) 3 Publications Verification	Integrin	Cancer
Cyclo(RGDyK) is a potent and selective α_Vβ₃ integrin inhibitor with an IC₅₀ of 20 nM.

HY-P1897

Fibronectin Active Fragment Control	Integrin	Inflammation/Immunology
Fibronectin Active Fragment Control is an active peptide fragment of fibronectin. Fibronectin is a glycoprotein interacting with integrins .

HY-12290A

Arg-Gly-Asp-Ser TFA RGDS peptide TFA; Fibronectin tetrapeptide TFA	Integrin	Inflammation/Immunology
Arg-Gly-Asp-Ser (TFA) is an integrin binding sequence that inhibits integrin receptor function. Arg-Gly-Asp-Ser (TFA) directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1 .

HY-P5038

Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) c(GRGDSP)	Integrin	Cancer
Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) (c(GRGDSP)) is an RGD-containing inhibitory peptide. Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) is a synthetic α5β1 *integrin* ligand that competitively inhibits the binding of invasin (Inv) to α5β1 integrin expressed on Caco-2 cells .

HY-P0278

RGD 5+ Cited Publications	Integrin	Cancer
RGD is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; binds to *integrins*.

HY-P6351

c(avb6)-DOTA TFA	Integrin	Cancer
c(avb6)-DOTA TFA is a conjugate of the αvβ6 integrin selective peptide ring modified with DOTA chelator. The Lu(III) complex of c(avb6)-DOTA TFA has a comparable affinity for αvβ6 integrin (IC₅₀=0.8 nM) and can be used as a tumor diagnostic .

HY-P10038

mP6 Myr-FEEERA-OH	Integrin	Infection
mP6 (Myr-FEEERA-OH) is a myristoylated peptide. mP6 inhibits the interaction of Gα₁₃ with integrin β₃ without disrupting talin-dependent integrin function. mP6 can block the GTP usage of Rac1, Rap1, and Rab7, effectively inhibiting the infection of CHO-A24 cells .

HY-P0278A

RGD Trifluoroacetate 5+ Cited Publications	Integrin	Cancer
RGD Trifluoroacetate is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; RGD Trifluoroacetate binds to *integrins*.

HY-P1188

LDV-FITC	Integrin	Cancer
LDV-FITC, a fluorescent peptide, is a FITC-conjugated LDV peptide (HY-P2267). LDV-FITC binds to the α4β1 integrin with high affinity (K_d: 0.3 nM and 12 nM for binding to U937 cells in the presence and absence of Mn ²⁺ respectively). LDV-FITC can be used to detect α4β1 integrin affinity .

HY-P3530

G-{d-Arg}-GDSP	Integrin	Others
G-{d-Arg}-GDSP is an RGD peptide analogue that binds to the adhesion receptor of integrins and inhibits cellular fibronectin attachment as well as osteoclast resorption .

HY-P0031

Cyclo(RADfK) 1 Publications Verification	Integrin	Others
Cyclo(RADfK) is a selective α(v)β(3) integrin ligand that has been extensively used for research, therapy, and diagnosis of neoangiogenesis.

HY-P1188A

LDV-FITC TFA	Integrin	Cancer
LDV-FITC TFA, a fluorescent peptide, is a FITC-conjugated LDV peptide (HY-P2267). LDV-FITC TFA binds to the α4β1 integrin with high affinity (K_d: 0.3 nM and 12 nM for binding to U937 cells in the presence and absence of Mn ²⁺ respectively). LDV-FITC TFA can be used to detect α4β1 integrin affinity .

HY-P6438

Alkyne-cRGD	Integrin	Others Cancer
Alkyne-cRGD is an integrin ligand. Alkyne-cRGD can be used in the study of degraders. Alkyne-cRGD undergoes copper-catalyzed azide-alkyne cycloaddition reaction .

HY-P4903

RGD-targeted Proapoptotic Peptide	Peptides	Cancer
RGD-targeted Proapoptotic Peptide is a peptide. The C-terminal RGD-4C peptide (ACDCRGDCFC) binds preferentially to integrins at sites of tumor angiogenesis.

HY-P5929

VnP-16	Integrin FAK	Inflammation/Immunology
VnP-16 can promote bone formation by accelerating osteoblast differentiation and activity through direct interaction with β1 integrin followed by FAK activation .

HY-P5287

cRGDfK-thioacetyl ester	Integrin	Cancer
cRGDfK-thioacetyl ester is a bioactive polypeptide molecule. cRGDfK peptide has a selective affinity for *integrins*. cRGDfK peptide can modify NIR fluorescent probes for cancer targeting imaging .

HY-P5287A

cRGDfK-thioacetyl ester TFA	Integrin	Cancer
cRGDfK-thioacetyl ester TFA is a bioactive polypeptide molecule. cRGDfK peptide has a selective affinity for *integrins*. cRGDfK peptide can modify NIR fluorescent probes for cancer targeting imaging .

HY-P1187

HSDVHK-NH2	Integrin	Cancer
HSDVHK-NH2 is an antagonist of the integrin αvβ3-vitronectin interaction, with an IC₅₀ of 1.74 pg/mL (2.414 pM) .

HY-P1187A

HSDVHK-NH2 TFA	Integrin	Cancer
HSDVHK-NH2 TFA is an antagonist of the integrin αvβ3-vitronectin interaction, with an IC₅₀ of 1.74 pg/mL (2.414 pM) .

HY-125053A

Batifiban TFA	Glycoprotein VI	Cardiovascular Disease
Batifiban TFA, a cyclic peptide, is an antagonist of platelet glycoprotein GPⅡb/Ⅲa and inhibits platelet aggregation. Batifiban blocks the binding of circulating vitronectin to integrin ανβ3 .

Cat. No.	Product Name	Target	Research Area

HY-P9984

Etrolizumab 2 Publications Verification rhuMAb Beta7; RG7413; PRO145223	Integrin	Cancer
Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with K_i values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD) .

HY-P990643

OS-2966	Integrin	Inflammation/Immunology
OS-2966 is a humanized antibody expressed in CHO cells, targeting Integrin b1/ITGB1/CD29. OS-2966 carries a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.5 kDa. The isotype control for OS-2966 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-108831A

Natalizumab (Solution) 2 Publications Verification	Integrin	Inflammation/Immunology Cancer
Natalizumab (Solution) is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses .

HY-P99184

Abrilumab	Integrin	Infection Inflammation/Immunology Cancer
Abrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD) .

HY-P990203

*Anti-Mouse LPAM-1/Integrin* α4β7 Antibody (DATK32)** 1 Publications Verification	Inhibitory Antibodies	Others
Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse LPAM-1/Integrin α4β7.

HY-P9911A

*Vedolizumab (anti-α4β7-integrin)*	Integrin	Inflammation/Immunology
Vedolizumab (anti-α4β7-integrin) is a humanized IgG1 monoclonal antibody that targets the α4β7 *integrin* for the treatment of ulcerative colitis and Crohn's disease .

HY-P9911

Vedolizumab 2 Publications Verification Anti-Human lymphocyte α4β7 integrin, Humanized Antibody	Integrin	Inflammation/Immunology Cancer
Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 *integrin* for the treatment of ulcerative colitis and Crohn's disease.

HY-P99560

Tadocizumab C4G1; YM-337	Integrin	Cardiovascular Disease
Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody tageting integrin αIIbβ3. Tadocizumab has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research .

HY-P990667

STX-100	Integrin	Inflammation/Immunology
STX-100 is a humanized antibody expressed in CHO cells, targeting Integrin aVb6 (ITGAV & ITGB6). STX-100 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.12 kDa. The isotype control for STX-100 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990207

*Anti-Mouse/Human Integrin* β7 Antibody (FIB504)**	Integrin	Others
Anti-Mouse/Human Integrin β7 Antibody (FIB504) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse/human Integrin β7.

HY-P99333

Volociximab M200; Eos 200-4	Integrin	Cardiovascular Disease Cancer
Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC₅₀=0.2 nM). Integrin α5β1 is a major fibronectin receptor involved in angiogenesis. Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs) .

HY-108831

Natalizumab 2 Publications Verification	Integrin	Inflammation/Immunology Cancer
Natalizumab is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses .

HY-P99291

Etaracizumab LM 609; MEDI 523; Anti-αvβ3 Integrin Recombinant Antibody	Integrin	Cancer
Etaracizumab (LM 609) is an α_vβ₃ integrin IgG1 monoclonal antibody. Etaracizumab inhibits angiogenesis and melanoma tumor growth. Etaracizumab can be used to research anticancer .

HY-P99946

Erlizumab rhuMAb	Inhibitory Antibodies	Inflammation/Immunology

HY-P990455

*Anti-Integrin* a11/ITAG11 Antibody**	Inhibitory Antibodies	Inflammation/Immunology

HY-P990456

*Anti-Integrin* b7/ITGB7 Antibody**	Inhibitory Antibodies	Inflammation/Immunology

HY-P99183

Abituzumab EMD 525797; DI17E6	Integrin	Cancer
Abituzumab (DI17E6) is a humanised anti-integrin αV monoclonal antibody (IgG2 type). Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W008859

Tetrac 1 Publications Verification Tetraiodothyroacetic acid; 3,3',5,5'-Tetraiodothyroacetic acid	Structural Classification Monophenols Classification of Application Fields Ketones, Aldehydes, Acids Source classification Phenols Endogenous metabolite Disease Research Fields Cancer	Integrin Endogenous Metabolite
Tetrac (Tetraiodothyroacetic acid), a derivative of L-thyroxine (T4), is a thyrointegrin receptor antagonist. Tetrac blocks the actions of T4 and 3,5,3'-triiodo-L-thyronine (T3) at the cell surface receptor for thyroid hormone on integrin αvβ3. Tetra has anti-angiogenic and anti-tumor activities .

HY-P3160

Fibronectin 3 Publications Verification	Cardiovascular Disease Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	Integrin
Fibronectin, a glycoprotein present in blood as well as in cells, is a biomarker of tissue injury. Fibronectin binds to membrane-spanning receptor proteins called integrins. Fibronectin also binds to other extracellular matrix proteins such as collagen, fibrin, and heparan sulfate proteoglycans .

HY-W654264

2-Methylbutyrylcarnitine chloride	Cardiovascular Disease Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite Integrin
2-Methylbutyrylcarnitine (chloride) is a gut microbial metabolite which binds to integrin α2β1 in platelets, potentiating cytosolic phospholipase A2 (cPLA2) activation and platelet hyperresponsiveness. 2-Methylbutyrylcarnitine (chloride) enhances platelet hyperreactivity and thrombus formation in mice. 2-Methylbutyrylcarnitine (chloride) is a branched-chain acylcarnitine .

HY-N2587

Irigenin	Structural Classification Flavonoids Iridaceae Classification of Application Fields Source classification Phenols Polyphenols Plants Belamcanda chinensis (Linn.) Redouté Disease Research Fields Isoflavones Cancer	Integrin Apoptosis
Irigenin is a is a lead compound, and mediates its anti-metastatic effect by specifically and selectively blocking α9β1 and α4β1 integrins binding sites on C-C loop of Extra Domain A (EDA). Irigenin shows anti-cancer properties. It sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells .

HY-N0031

Plantamajoside 1 Publications Verification	Plantaginaceae Structural Classification Classification of Application Fields Simple Phenylpropanols Source classification Phenols Polyphenols Phenylpropanoids Plantago asiatica L. Plants Inflammation/Immunology Disease Research Fields	NF-κB PI3K Akt Apoptosis Autophagy p38 MAPK Src
Plantamajoside is an orally active phenylpropanoid glycoside. Plantamajoside can be isolated from Plantago asiatica L.(Plantaginaceae). Plantamajoside inactivates NF-κB, PI3K/akt, induces Apoptosis, and improves Autophagy. Plantamajoside regulates MAPK, integrin-linked kinase/c-Src. Plantamajoside inhibits multiple cancers, improves lung and kidney damage. Plantamajoside has neuroprotective and anti-inflammatory effects .

HY-136699

Excisanin A	Structural Classification Terpenoids Labiatae Source classification Diterpenoids Baccharis densiflora Wedd. Plants	MMP FAK Src Integrin
Excisanin A is a potent anticancer agent. Excisanin A inhibits cell proliferation, migration, adhesion and invasion. Excisanin A decreases the expression of MMP-2, MMP-9, p-FAK, p-Src, integrin β1 protein. Excisanin A has the potential for the research of breast cancer .

HY-122552

Chrysotobibenzyl	Structural Classification Natural Products Orchidaceae Source classification Plants Dendrobium pulchellum Roxb. et Lindl. :Lindl.	Integrin
Chrysotobibenzyl can be isolated from stem of Dendrobium pulchellum. Chrysotobibenzyl inhibits lung cancer cell (H460 and H292) migration, invasion, filopodia formation via Cav-1, integrins β1, β3, and αν, and EMT suppressions. Chrysotobibenzyl also sensitizes lung cancer cell death mediated by Cisplatin (HY-17394) .

HY-N2587R

Irigenin (Standard)	Structural Classification Flavonoids Iridaceae Source classification Phenols Polyphenols Plants Belamcanda chinensis (Linn.) Redouté Isoflavones	Integrin Apoptosis
Irigenin (Standard) is the analytical standard of Irigenin. This product is intended for research and analytical applications. Irigenin is a is a lead compound, and mediates its anti-metastatic effect by specifically and selectively blocking α9β1 and α4β1 integrins binding sites on C-C loop of Extra Domain A (EDA). Irigenin shows anti-cancer properties. It sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells .

HY-N0031R

Plantamajoside (Standard)	Plantaginaceae Structural Classification Simple Phenylpropanols Source classification Phenols Polyphenols Phenylpropanoids Plantago asiatica L. Plants	NF-κB PI3K Apoptosis Autophagy p38 MAPK Src
Plantamajoside (Standard) is the analytical standard of Plantamajoside. This product is intended for use in research and analytical applications. Plantamajoside is an orally active phenylpropanoid glycoside. Plantamajoside can be isolated from Plantago asiatica L.(Plantaginaceae). Plantamajoside inactivates NF-κB, PI3K/akt, induces Apoptosis, and improves Autophagy. Plantamajoside regulates MAPK, integrin-linked kinase/c-Src. Plantamajoside inhibits multiple cancers, improves lung and kidney damage. Plantamajoside has neuroprotective and anti-inflammatory effects .

Cat. No.	Product Name	Chemical Structure

HY-113439S

12-HETE-d8
12-HETE-d₈ is the deuterium labeled 12-HETE. 12-HETE, a major metabolic product of arachidonic acid using 12-LOX catalysis, inhibits cell apoptosis in a dose-dependent manner. 12-HETE promotes the activation and nuclear translocation of NF-κB through the integrin-linked kinase (ILK) pathway[1].12-HETE has both anti-thrombotic and pro-thrombotic effects[2]. 12-HETE is a neuromodulator[3].

HY-19344S2

Lifitegrast-d4-1

Lifitegrast-d₄-1 is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

HY-19344S1

Lifitegrast-d6

Lifitegrast-d₆ (SAR 1118-d₆) is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

HY-19344S

Lifitegrast-d4

Lifitegrast-d₄ (SAR 1118-d₄) is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

integrins

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Natural
Products